《高盛認股證牛熊證》藥明半年回調逾4成 股價近日橫行整固 留意貼價購18980、中期購19984,遠牛59944
正股表現:藥明生物(2269)自月中低位反彈後近日橫行整固,今早股價回調。早段低見84.05元的一週低位後跌幅收窄。現報87.25元,微跌約0.2%。
據藥明報表披露,藥明於昨日在聯交所回購344.8萬股,涉資約3億元。而本年至今,藥明已共回購2,766.65萬股,佔藥明股本0.65%。
資金流向:觀察個股輪證資金流向,可見認購證於昨日獲資金轉向流入,有約20萬元。認沽證於上週五及本週二共錄得約20萬元資金流入後,昨日獲資金轉向沽出。
牛熊證方面,昨日流入牛證的資金集中在80元收回區域的產品。熊證則較集中在100元收回區域的產品。
產品選擇:投資者如看好,認購證方面的貼價選擇可留意年期約9個月的低街貨藥明購18980。中期選擇可留意低街貨藥明購19984。牛證方面的近牛選擇可留意藥明牛60587,遠牛選擇可留意藥明牛59944,與現價有約7及12元收回距離。
藥明購18980,行使價90元,2022年09月28日到期,實際槓桿2.9倍,貼價、低街貨
藥明購19984,行使價96.93元,2022年06月23日到期,實際槓桿3.5倍,中期、低街貨
藥明牛60587,收回價80元,行使價78.5元,換股比率100,槓桿比率8.8倍,相近收回價近牛中槓桿最高
藥明牛59944,收回價75元,行使價73.5元,換股比率100,槓桿比率5.8倍,相近收回價遠牛中槓桿最高
投資者如看淡,可留意屬遠熊的藥明熊61312,與現價有約12元收回距離。
藥明熊61312,收回價100元,行使價101.5元,換股比率100,槓桿比率5.6倍,近12元收回距離遠熊
註: 以上數據資料來自高盛認股證牛熊證網站https://www.gswarrants.com.hk/
~
重要聲明:
以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.